Significant progress has been made in the search for perfection regarding management of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer. As our understanding of the physiologic aspects of this complex side effect expands, new targets and novel antiemetic therapies will continue to emerge. The substantial gains achieved with the introduction of 5-hydroxytryptamine (5-HT3) and neurokinin-1 (NK-1) receptor antagonists provide evidence that these physiologic insights can be translated into active therapies that improve patient care \[[@CR1]\].

Strategies for CINV prevention and management will undoubtedly continue to evolve as the treatment landscape for cancer steadily advances. The demand for more effective, better tolerated cancer therapy continues to drive development of novel chemotherapeutic agents and targeted therapies. The emetogenic potential of these novel agents vary greatly, with many emerging therapies not yet classified or included in current antiemetic guidelines \[[@CR2]--[@CR4]\]. Oral chemotherapeutic agents and targeted therapies are often administered daily for extended periods of time, requiring special considerations for prevention of treatment-related nausea and vomiting \[[@CR5]\].

The future of chemotherapy will likely include additional oral agents to ease drug administration and lower clinical costs, as well as the continued development of antibody-drug conjugates (ADCs) \[[@CR6], [@CR7]\]. ADCs consist of a potent cytotoxic agent joined to a monoclonal antibody via a cleavable linker, allowing chemotherapeutic agents to be directed to tumor-specific receptors \[[@CR7]\]. This prevents damage to normal tissues and reduces side effects, such as nausea and vomiting. This evolution in the approach to chemotherapy will potentially reduce the incidence of CINV, although traditional chemotherapy with platinum agents, anthracyclines, and alkylating agents will remain an important component of cancer therapy, particularly in the curative/adjuvant setting.

The efficacy of NK-1 receptor antagonists, coupled with the modest impact of 5-HT3 receptor antagonists to prevent delayed CINV, illustrates the need to include NK-1 receptor antagonists in antiemetic treatment regimens for patients at risk for delayed CINV \[[@CR1]\]. The lack of head-to-head comparison trials complicates treatment selection. Each antiemetic therapy offers specific advantages and disadvantages that should be taken into consideration when selecting therapy. For example, non-oral formulations such as transdermal or extended release subcutaneous granisetron, intravenous fosaprepitant, and the new intravenous formulations of aprepitant and rolapitant represent good treatment options for patients who are unable to take or retain oral medications, including those who have difficulty swallowing, oral mucositis, or limited gut motility and/or absorption \[[@CR8]--[@CR11]\]. This reduction in pill burden can improve patient adherence to both antiemetic and anticancer treatment. In addition, netupitant/palonosetron (NEPA) offers a convenient single capsule option for patients requiring antiemetic therapy that includes both a 5-HT3 and NK-1 receptor antagonist \[[@CR12]\]. Rolapitant shows a different interaction with concomitant therapies, which can be an important factor for patients receiving multiple cancer therapies and supportive care measures \[[@CR13]\]. Olanzapine can be considered an alternative option for some patients with CINV and appears to be an important agent in prevention of nausea \[[@CR14]\].

Ultimately, no presently available antiemetic therapy alone will provide complete protection from the nausea and vomiting associated with chemotherapy across the different emetogenic phases. Ongoing trials are exploring antiemetic therapies in pediatric and adolescent patients, as well as those with refractory CINV, to expand the reach of currently available and novel approaches for CINV management \[[@CR15]\]. Specific areas of unmet needs in CINV, such as nausea and anticipatory CINV, need to be addressed in future clinical research to identify the mechanisms involved in these responses and the potential strategies to overcome these extremely bothersome side effects \[[@CR16], [@CR17]\]. The role for olanzapine in nausea control continues to be explored in ongoing studies of patients receiving emetogenic chemotherapy for solid tumors and hematologic malignancies \[[@CR15]\]. Nausea should be included as a primary study endpoint in future clinical trial designs to better measure the efficacy of CINV therapies and reflect patients' true experience \[[@CR16]\]. The control arms for ongoing clinical trials also need to include guideline-based antiemetic therapy to provide insightful comparison data that can shape future management of CINV \[[@CR18]\].

Patient-related risk factors, including genetic differences in cytochrome P450 or 5-HT3 mutations and ethnic differences, have also been insufficiently evaluated, with emerging risk models and new suggestions for risk-adapted antiemetic therapy representing a promising pathway for better results in many situations \[[@CR19], [@CR20]\]. Novel antiemetic therapies and combination approaches to overcome delayed CINV and breakthrough/refractory CINV are another focus of ongoing investigation and seek to achieve better control of nausea and vomiting after chemotherapy \[[@CR21]\]. Effective education of the multidisciplinary healthcare team, including physicians, nurses, and pharmacists, regarding current CINV guidelines and emerging therapeutic options will likely improve the use of these regimens \[[@CR1]\]. In addition, patients must be informed of their risk for CINV, the importance of timely reporting of symptoms, and the antiemetic therapies available for their use. By working together, patients and clinicians can continue to strive for perfection and make nausea and vomiting associated with chemotherapy a thing of the past.
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